RecruitingNot ApplicableNCT05487846

Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation

ADVANTAGE: Addressing Disparities for Veterans and African Americans Through Peer-Navigation for Testing and Genetic Evaluation


Sponsor

Thomas Jefferson University

Enrollment

120 participants

Start Date

Jan 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical trial evaluates whether having a trained peer navigator helps African American men with prostate cancer that has spread to other parts of the body (metastatic) understand and navigate the genetic testing process better than not having a peer navigator. Genetic testing for men with prostate cancer is very important for making treatment and management decisions. However, understanding the risks, benefits, and steps of genetic counseling and testing can be very challenging for patients. African American men are especially less likely to participant in genetic testing due to lack of awareness or understanding, cultural beliefs, finances, or mistrust of the healthcare system. A peer navigator, someone who helps a patient through the information and the process, may be helpful to some men. This study evaluates whether having a peer navigator throughout the genetic evaluation process helps patients understand and engage in the process more.


Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria6

  • Provide signed and dated informed consent form
  • English speaking only
  • Willing to comply with all study procedures and be available for the duration of the study
  • Any individual \>= 18 years old
  • African American men who meet National Comprehensive Cancer Network (NCCN) criteria for testing will be offered participation. These criteria include any one of the following: (1) metastatic prostate cancer (PCA); (2) intraductal or ductal pathology; (3) T3a or higher; (4) grade group 4 or Gleason 8 or higher; (5) family history of breast, ovarian, prostate, pancreatic, colorectal, or uterine cancers in 3 or more blood relatives particularly if diagnosed at age \< 50. These criteria have been adapted from the NCCN Prostate Cancer (version 2.2021) and NCCN Breast, Ovarian, and Pancreatic (version 2.2021) guideline
  • Anyone who has trouble understanding the consent or with significant anxiety detected during the consent process will also be excluded

Interventions

BEHAVIORALPatient Navigation

Receive peer navigation services

OTHERGenetic Counseling

Receive genetic counseling

OTHERSurvey Administration

Ancillary studies

OTHERBest Practice

Receive standard care

OTHERGenetic Counseling

Receive genetic counseling

OTHERSurvey Administration

Ancillary studies


Locations(1)

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05487846


Related Trials